Dominari (DOMH) 10-Q 9 Aug 23 2023 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2023	Aug. 08, 2023
Document Information Line Items
Entity Registrant Name	DOMINARI HOLDINGS INC.
Trading Symbol	DOMH
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		5,345,312
Amendment Flag	false
Entity Central Index Key	0000012239
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-05576
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	52-0849320
Entity Address, Address Line One	725 5th Avenue
Entity Address, Address Line Two	22nd Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10022
City Area Code	(703)
Local Phone Number	992-9325
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, $0.0001 par value
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 3,598	$ 33,174
Marketable securities	20,675	7,130
Deposits with clearing broker	7,082
Prepaid expenses and other assets	715	564
Prepaid acquisition cost		301
Short-term investments, at fair value	13	13
Notes receivable, at fair value - current portion	6,339	7,474
Investment in Fieldpoint Securities		2,000
Total current assets	38,422	50,656
Property and equipment, net	387
Notes receivable, at fair value - non-current portion	1,622	1,100
Employee forgivable loan receivable	98
Investments	23,178	23,103
Right-of-use assets	3,530	919
Security deposit	458	458
Total assets	67,695	76,236
Current liabilities
Accounts payable and accrued expenses	232	447
Accrued salaries and benefits	632	1,260
Income taxes withheld	1,300
Accrued Commissions	17
Lease liability - current	353	82
Other Current liability	124
Total current liabilities	2,658	1,789
Lease liability	3,259	680
Total liabilities	5,917	2,469
Stockholders’ equity
Preferred stock value
Common stock, $0.0001 par value, 100,000,000 shares authorized; 5,345,312 and 5,485,096 shares issued at June 30, 2023 and December 31, 2022, respectively; 5,285,164 and 5,017,079 shares outstanding at June 30, 2023 and December 31, 2022, respectively
Additional paid-in capital	260,585	262,970
Treasury stock, at cost, 60,148 and 468,017 shares at June 30, 2023 and December 31, 2022, respectively	(501)	(3,322)
Accumulated deficit	(198,306)	(185,881)
Total stockholders’ equity	61,778	73,767
Total liabilities and stockholders’ equity	67,695	76,236
Series D Preferred Stock
Stockholders’ equity
Preferred stock value
Series D-1 Preferred Stock
Stockholders’ equity
Preferred stock value

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized	50,000,000	50,000,000
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	5,345,312	5,485,096
Common stock, shares outstanding	5,285,164	5,017,079
Treasury stock, at cost	60,148	468,017
Series D Preferred Stock
Preferred stock, authorized	5,000,000	5,000,000
Preferred stock, issued	3,825	3,825
Preferred stock, outstanding	3,825	3,825
Liquidation preference (in Dollars per share)	$ 0.0001	$ 0.0001
Series D-1 Preferred Stock
Preferred stock, authorized	5,000,000	5,000,000
Preferred stock, issued	834	834
Preferred stock, outstanding	834	834
Liquidation preference (in Dollars per share)	$ 0.0001	$ 0.0001

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Revenues	$ 71		$ 71
Operating costs and expenses
General and administrative	9,080	2,262	12,913	4,049
Research and development	2	36	3	2,052
Total operating expenses	9,082	2,298	12,916	6,101
Loss from operations	(9,011)	(2,298)	(12,845)	(6,101)
Other income (expenses)
Other income				64
Interest income	160	220	297	399
Gain (loss) on marketable securities	400	(2,239)	335	(2,736)
Unrealized loss on note receivable	(212)		(212)
Change in fair value of investments		(760)		(238)
Total other income (expenses)	348	(2,779)	420	(2,511)
Net loss	(8,663)	(5,077)	(12,425)	(8,612)
Deemed dividends related to Series O and Series P Redeemable Convertible Preferred Stock		(1,100)		(4,109)
Net Loss Attributable to Common Shareholders	$ (8,663)	$ (6,177)	$ (12,425)	$ (12,721)
Net loss per share, basic and diluted
Basic (in Dollars per share)	$ (1.79)	$ (1.18)	$ (2.45)	$ (2.42)
Weighted average number of shares outstanding, basic and diluted
Basic (in Shares)	4,827,239	5,251,023	5,065,055	5,251,766

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Diluted	$ (1.79)	$ (1.18)	$ (2.45)	$ (2.42)
Diluted	4,827,239	5,251,023	5,065,055	5,251,766

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity - USD ($) $ in Thousands	Redeemable Convertible Preferred Stock Series O	Redeemable Convertible Preferred Stock Series P	Preferred Stock	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Deficit	Total
Balance at Dec. 31, 2021					$ 265,633	$ (264)	$ (163,774)	$ 101,595
Balance (in Shares) at Dec. 31, 2021			4,659	5,275,329
Redemption of Series O Redeemable Convertible Preferred Stock	$ (11,000)
Redemption of Series O Redeemable Convertible Preferred Stock (in Shares)	(11,000)
Redemption of Series P Redeemable Convertible Preferred Stock		$ (11,000)
Redemption of Series P Redeemable Convertible Preferred Stock (in Shares)		(11,000)
Issuance of Series O redeemable convertible preferred stock for cash	$ 11,000
Issuance of Series O redeemable convertible preferred stock for cash (in Shares)	11,000
Issuance of Series P redeemable convertible preferred stock for cash		$ 11,000
Issuance of Series P redeemable convertible preferred stock for cash (in Shares)		11,000
Cost on issuance of Series O and Series P Redeemable Convertible Preferred Stock	(1,504)	$ (1,505)
Deemed dividends related to Series O and Series P Redeemable Convertible Preferred Stock	1,504	1,505			(4,109)			(4,109)
Repurchase of treasury stock						$ (1,486)		(1,486)
Repurchase of treasury stock (in Shares)						242,902
Stock-based compensation					105			105
Cancellation of common stock related to investment in CBM
Cancellation of common stock related to investment in CBM (in Shares)				(22,812)
Fractional shares adjusted for reverse split					(26)			(26)
Fractional shares adjusted for reverse split (in Shares)				(5,665)
Net loss							(8,612)	(8,612)
Balance at Jun. 30, 2022					261,603	$ (1,750)	(172,386)	87,467
Balance (in Shares) at Jun. 30, 2022			4,659	5,246,852		242,902
Balance at Mar. 31, 2022	$ 11,000	$ 11,000			262,624	$ (264)	(167,309)	95,051
Balance (in Shares) at Mar. 31, 2022	11,000	11,000	4,659	5,252,517
Redemption of Series O Redeemable Convertible Preferred Stock	$ (11,000)
Redemption of Series O Redeemable Convertible Preferred Stock (in Shares)	(11,000)
Redemption of Series P Redeemable Convertible Preferred Stock		$ (11,000)
Redemption of Series P Redeemable Convertible Preferred Stock (in Shares)		(11,000)
Deemed dividends related to Series O and Series P Redeemable Convertible Preferred Stock					(1,100)			(1,100)
Repurchase of treasury stock						$ (1,486)		(1,486)
Repurchase of treasury stock (in Shares)						242,902
Stock-based compensation					105			105
Fractional shares adjusted for reverse split					(26)			(26)
Fractional shares adjusted for reverse split (in Shares)				(5,665)
Net loss							(5,077)	(5,077)
Balance at Jun. 30, 2022					261,603	$ (1,750)	(172,386)	87,467
Balance (in Shares) at Jun. 30, 2022			4,659	5,246,852		242,902
Balance at Dec. 31, 2022					262,970	$ (3,322)	(185,881)	73,767
Balance (in Shares) at Dec. 31, 2022			4,659	5,485,096		468,017
Stock-based compensation					1,375			1,375
Stock-based compensation (in Shares)				529,715
Cancellation of common stock
Cancellation of common stock (in Shares)				(25,000)
Purchase of treasury stock (in Shares)						(939,000)		(939,000)
Purchase of treasury stock (in Shares)						236,630
Retirement of treasury stock					$ (3,760)	$ 3,760
Retirement of treasury stock (in Shares)				(644,499)		(644,499)
Net loss							(12,425)	(12,425)
Balance at Jun. 30, 2023					260,585	$ (501)	(198,306)	61,778
Balance (in Shares) at Jun. 30, 2023			4,659	5,345,312		60,148
Balance at Mar. 31, 2023					259,215	$ (501)	(189,643)	69,071
Balance (in Shares) at Mar. 31, 2023			4,659	4,815,597		60,148
Stock-based compensation					1,370			1,370
Stock-based compensation (in Shares)				529,715
Net loss							(8,663)	(8,663)
Balance at Jun. 30, 2023					$ 260,585	$ (501)	$ (198,306)	$ 61,778
Balance (in Shares) at Jun. 30, 2023			4,659	5,345,312		60,148

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities
Net loss	$ (12,425)	$ (8,612)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of right-of-use assets	182
Depreciation	32
Change in fair value of short-term investment		1,646
Change in fair value of long-term investment		(1,408)
Stock-based compensation	2,675	105
Realized loss on marketable securities	487	568
Unrealized (gain) loss on marketable securities	(514)	2,299
Unrealized loss on note receivable	212
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(229)	153
Prepaid acquisition cost	301
Deposits with clearing broker	(3,532)
Accounts payable and accrued expenses	(428)	(239)
Accrued salaries and benefits	(628)	7
Accrued commissions	(8)
Lease liabilities	58
Other current liabilities	3
Notes receivable, at fair value – net interest accrued	(99)	(377)
Deposit		8
Net cash used in operating activities	(13,913)	(5,850)
Cash flows from investing activities
Purchase of marketable securities	(34,014)	(27,460)
Sale of marketable securities	20,494	28,272
Proceeds from sale of digital currencies		93
Purchase of fixed assets	(419)
Acquisition of FPS, net of cash acquired and receivable owed from FPS	(1,112)
Collection of principal on note receivable	502
Funds to employee forgivable loan	(100)
Purchase of short-term and long-term investments	(75)	(14,605)
Purchase of short-term and long-term promissory notes		(1,600)
Net cash used in investing activities	(14,724)	(15,300)
Cash flows from financing activities
Proceeds from issuance of Series O and Series P Redeemable Convertible Preferred Stock, net of discount and offering cost		17,891
Payment for fractional shares		(26)
Redemption of Series O and Series P Redeemable Convertible Preferred Stock		(22,000)
Purchase of treasury stock	(939)	(1,486)
Net cash used in financing activities	(939)	(5,621)
Net decrease in cash and cash equivalents and restricted cash	(29,576)	(26,771)
Cash and cash equivalents, beginning of period	33,174	65,562
Cash and cash equivalents, end of period	3,598	38,791
Non-cash investing and financing activities
Transfer from short-term investment to marketable securities		1,482
Reclassify from convertible note receivable to notes receivable at fair value		2,147
Promissory convertible note receivable conversion into common shares		$ 1,508
On March 27, 2023, the Company acquired all assets and liabilities of FPS as disclosed in Note 4:
Net assets acquired, net of cash acquired and receivable owed from FPS	3,112
Less - Deposit previously transferred in October 2022 to FPS	(2,000)
Net cash paid	$ 1,112

Organization and Description of

Organization and Description of Business and Recent Developments	6 Months Ended
	Jun. 30, 2023
Organization and Description of Business and Recent Developments [Abstract]
Organization and Description of Business and Recent Developments	Note 1. Organization and Description of Business and Recent Developments Organization and Description of Business Dominari Holdings Inc. (the “Company”), formerly AIkido Pharma, Inc., was founded in 1967 as Spherix Incorporated. Since 2017, the Company has operated as a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics and their related patent technology. In an effort to enhance shareholder value, in June of 2022, the Company formed a wholly owned financial services subsidiary, Dominari Financial Inc. (“Dominari Financial”), with the intent of shifting the Company’s primary operating focus away from biotechnology to the fintech and financial services industries. Through Dominari Financial, the Company acquired Dominari Securities LLC (“Dominari Securities”), an introducing broker-dealer, registered with the Financial Industry Regulatory Authority (“FINRA”) and an investment adviser registered with the Securities and Exchange Commission (“SEC”). Dominari Securities provides investment advisory services and annuity and insurance products of certain insurance carriers as an insurance agency through independent and affiliated brokers. Additionally, AIkido Labs, LLC (“Aikido Labs”), another wholly owned subsidiary of the Company, is in the process of winding down its historical pipeline of biotechnology assets consisting of patented technologies from leading universities and researchers, including prospective treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. Aikido Labs has historically explored opportunities in high growth industries and has equity holdings including Anduril Industries, Inc, Databricks, Inc., Discord, Inc., Epic Games, Inc., Payward, Inc. dba Kraken, Space Exploration Technologies Corp. dba SpaceX, Tevva Motors Ltd., Thrasio, LLC, and Yanka Industries, Inc. dba Masterclass.

Liquidity and Capital Resources

Liquidity and Capital Resources	6 Months Ended
	Jun. 30, 2023
Liquidity and Capital Resources [Abstract]
Liquidity and Capital Resources	Note 2. Liquidity and Capital Resources The Company continues to incur ongoing administrative and other expenses, including public company expenses, in excess of corresponding (non-financing related) revenue. While the Company continues to implement its business strategy, it intends to finance its activities through managing current cash on hand from the Company’s past equity offerings. Based upon projected cash flow requirements, the Company has adequate cash and cash equivalents and marketable securities to fund its operations for at least the next twelve months from the date of the issuance of these unaudited condensed consolidated financial statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3. Summary of Significant Accounting Policies There have been no material changes in the Company’s significant accounting policies from those previously disclosed in the 2022 Annual Report other than those discussed below. Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”), and in conformity with the rules and regulations of the SEC. In the opinion of management, these financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the results of the interim periods presented. The condensed balance sheet at December 31, 2022, was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements. Accordingly, these financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aikido Labs, Dominari Financial, and Dominari Securities. All significant intercompany balances and transactions have been eliminated in consolidation. Results for interim periods are not necessarily indicative of results to be expected for a full year or any future period. Use of Estimates The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, the valuation of investments, the valuation of notes receivable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions. Deposits with clearing broker Deposits with Dominari Securities’ clearing broker consisted of approximately $7.1 million held in money market funds and liquid insured deposits maintained by the Company with its clearing broker as of June 30, 2023. Leases The Company accounts for its leases under ASC 842, Leases Leases Revenue The Company recognizes revenues under ASC 606 - Revenue from Contracts with Customers . The following provides detailed information on the recognition of the Company’s revenues from contracts with customers: ● Underwriting services include underwriting and placement agent services in both the equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenues are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. Costs associated with underwriting transactions are deferred until the related revenue is recognized or the engagement is otherwise concluded and are recorded on a gross basis within the general and administrative line item in the unaudited condensed consolidated statements of operations as the Company is acting as a principal in the arrangement. Any expenses reimbursed by the Company’s clients are recognized as other income. ● Commissions are earned by executing, transactions for clients primarily in equity, equity-related, and debt products. Commission revenues associated with trade execution are recognized at a point in time on trade-date. Commissions revenues are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date. Recently adopted accounting standards In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers Effect of new accounting pronouncements not yet adopted In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions . In March 2023, the FASB issued ASU 2023-01, Leases Effect of new accounting pronouncements to be adopted in future periods The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these unaudited condensed consolidated financial statements.

FPS Acquisition

FPS Acquisition	6 Months Ended
	Jun. 30, 2023
FPS Acquisition [Abstract]
FPS Acquisition	Note 4. FPS Acquisition On September 9, 2022, Dominari Financial entered into a membership interest purchase agreement, as amended and restated on March 27, 2023 (the “FPS Purchase Agreement”) with Fieldpoint Private Bank & Trust (“Seller”), a Connecticut bank, for the purchase of its wholly owned subsidiary, Fieldpoint Private Securities, LLC, a Connecticut limited liability company (“FPS”), that is a broker-dealer registered with FINRA and an investment adviser registered with the SEC (the “FPS Acquisition”). Pursuant to the terms of the FPS Purchase Agreement, Dominari Financial purchased from the Seller 100% of the membership interests in FPS (the “FPS Membership Interests”). FPS’s registered broker-dealer and investment adviser businesses were renamed and will operate as Dominari Securities, a wholly owned subsidiary of Dominari Financial. The FPS Purchase Agreement provides for Dominari Financial’s acquisition of FPS’s Membership Interests in two closings, the first of which occurred on October 4, 2022 (the “Initial Closing”), at which Dominari Financial paid to the Seller $2.0 million in consideration for a transfer by the Seller to Dominari Financial of 20% of the FPS Membership Interests. Following the Initial Closing, FPS filed a continuing membership application requesting approval for a change of ownership, control, or business operations with FINRA in accordance with FINRA Rule 1017 (the “Rule 1017 Application”). The Rule 1017 Application was approved by FINRA on March 20, 2023. The second closing (the “Second Closing”) occurred on March 27, 2023. Dominari Financial paid to the Seller an additional approximate $1.6 million consideration for a transfer by the Seller to Dominari Financial of the remaining 80% of the FPS Membership Interests. Consideration Transferred The FPS Acquisition was accounted for as a business combination under ASC 805. Under the terms of the FPS Purchase Agreement and subsequent Amendments and Side Letters, 100% of the FPS Membership Interests were acquired for cash consideration of approximately $3.4 million, which reflected the fair value of net assets acquired, plus a $1 purchase price. At March 31, 2023, Dominari Financial had not finalized the purchase accounting related to the fair value of assets acquired in the FPS Acquisition. Pursuant to the Initial Closing and Second Closing, Dominari Financial had wired a total of approximately $3.6 million in cash to the Seller. The purchase price allocation identified net assets of approximately $3.4 million, resulting in a receivable due from the Seller for approximately $0.2 million. The receivable is not included within the consideration transferred as part of the FPS Acquisition but is included within prepaid expenses and other assets within the unaudited condensed consolidated balance sheet as of March 31, 2023. Under the acquisition method of accounting, the assets acquired, and liabilities assumed of FPS were recorded as of the acquisition date, at their respective fair values, and consolidated with those of the Company. Acquisition-related costs are not included as a component of consideration transferred but are expensed in the periods in which costs are incurred. The Company incurred approximately $0.3 million of transaction costs associated with the FPS Acquisition. The transaction costs are included in general and administrative expenses in the unaudited condensed consolidated statement of operations. Fair Value of Net Assets Acquired The following table summarizes the fair values of the assets acquired and liabilities assumed of FPS at the date of acquisition: March 27, 2023 (Unaudited) ASSETS Cash and cash equivalents $ 92 Deposits with Clearing Broker-Dealer 3,550 Other receivables 53 Prepaid and other current assets 89 Total assets acquired 3,784 Liabilities Accrued expenses $ 273 Accrued commissions 25 Wealth management liabilities 62 Total liabilities assumed 360 Total net assets of FPS Acquisition 3,424 Dominari Securities reported a net loss of approximately $7.7 million for the three-months ended June 30, 2023. Revenue for the period ended June 30, 2023, was approximately $0.07 million. The net loss was primarily a result of approximately $5.4 million of bonus and employee compensation expense and professional services of approximately $0.9 million. The bonus and compensation expense and professional service fees related to establishing the operations of the broker-dealer and are included in the general and administrative expenses line item within the unaudited condensed consolidated statement of operations.

Investments in Marketable Secur

Investments in Marketable Securities	6 Months Ended
	Jun. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Investments in Marketable Securities	Note 5. Investments in Marketable Securities The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the three and six months ended June 30, 2023 and 2022, which are recorded as a component of gains and (losses) on marketable securities on the unaudited condensed consolidated statements of operations, are as follows ($ in thousands): Three Months Ended Six Months Ended 2023 2022 2023 2022 Realized loss $ (432 ) $ (344 ) $ (487 ) $ (568 ) Unrealized gain (loss) 643 (1,967 ) 514 (2,299 ) Dividend income 188 72 308 131 Total $ 400 $ (2,239 ) $ 335 $ (2,736 )

Short-Term Investments

Short-Term Investments	6 Months Ended
	Jun. 30, 2023
Short-Term Investments [Abstract]
Short-term investments	Note 6. Short-term investments The following table presents the Company’s short-term investments as of June 30, 2023, and December 31, 2022 ($ in thousands): June 30, December 31, Investment in Vicinity Motor Corp. 13 13 Total 13 13 There was no change in the fair value of the short-term investments for the six months ended June 30, 2023. The following table provides quantitative information regarding Level 3 fair value measurement inputs at their measurement dates: June 30, December 31, Option term (in years) 1.3 1.8 Volatility 76.9 % 76.90 % Risk-free interest rate 4.47 % 4.47 % Expected dividends 0.00 % 0.00 % Stock price $ 0.96 $ 0.96

Long-Term Investments

Long-Term Investments	6 Months Ended
	Jun. 30, 2023
Long-Term Investments [Abstract]
Long-Term Investments	Note 7. Long-Term Investments The Company holds interests in several privately held companies as long-term investments that the Company perceives as potential IPO candidates. The following table presents the Company’s long-term investments as of June 30, 2023, and December 31, 2022 ($ in thousands): Cost Basis June 30, December 31, Investment in Kerna Health Inc $ 2,140 $ 4,940 $ 4,940 Investment in Kaya Now 1,500 - - Investment in Tevva Motors 1,972 2,794 2,794 Investment in ASP Isotopes 1,300 - - Investment in AerocarveUS Corporation 1,075 1,075 1,000 Investment in Qxpress 1,000 1,000 1,000 Investment in Masterclass 170 170 170 Investment in Kraken 597 597 597 Investment in Epic Games 3,500 3,500 3,500 Investment in Tesspay 1,240 2,500 2,500 Investment in SpaceX 3,500 3,674 3,674 Investment in Databricks 1,200 1,200 1,200 Investment in Discord 476 476 476 Investment in Thrasio 300 300 300 Investment in Automation Anywhere 476 476 476 Investment in Anduril 476 476 476 Total $ 20,922 $ 23,178 $ 23,103 Investment in AerocarveUS Corporation On November 22, 2021, the Company entered into an agreement (the “AerocarveUS Agreement”) with AerocarveUS Corporation, (“AerocarveUS”). Under the AerocarveUS Agreement, the Company agreed to purchase 250,000 shares of common stock of AerocarveUS for $1.0 million. AerocarveUS changed its name to “Unusual Machines, Inc.” on July 5, 2022. In March of 2023, the Company was issued an additional 64,377 shares at no cost. In June 2023, the Company purchased an additional 150,000 shares of common stock for approximately $0.08 million. The investment in AerocarveUS Corporation (a.k.a. Unusual Machines, Inc.) was valued at approximately $1.08 million as of June 30, 2023.

Notes Receivable

Notes Receivable	6 Months Ended
	Jun. 30, 2023
Notes Receivable [Abstract]
Notes Receivable	Note 8. Notes Receivable The following table presents the Company’s notes receivable as of June 30, 2023 ($ in thousands): Maturity Date Stated Interest Rate Principal Amount Interest Receivable Fair Value Notes receivable, at fair value Convergent convertible note - current 01/29/2023 8 % $ 1,000 $ 199 $ 1,199 Convergent convertible note - non-current 01/29/2023 8 % $ 500 $ - $ 500 Raefan Industries LLC Investment 12/31/2023 8 % $ 4,518 $ 623 $ 5,141 American Innovative Robotics Investment 04/01/2027 8 % $ 1,100 $ 22 $ 1,122 Notes receivable, at fair value - current portion $ 6,339 Notes receivable, at fair value - non-current portion $ 1,622 Convergent Therapeutics, Inc. Investment The Company’s 8% convertible promissory note (“Convergent Convertible Note”) issued by Convergent Therapeutics, Inc. (“Convergent”) in the principal amount of approximately $1.8 million pursuant to a Note Purchase Agreement matured on January 29, 2023. Upon maturity, Convergent entered into a contractual repayment schedule with the Company. Pursuant to the schedule, Convergent will make a total of eight payments in the amount of $250 thousand and accrued interest, every three months until fully satisfied. The principal balance of the Convergent Convertible Note was approximately $1.8 million as of June 30, 2023. The Company recorded principal repayment of $0.5 million and interest income of approximately $0.1 million on the Convergent Convertible Note for the six months ended June 30, 2023. Raefan Industries LLC Investment The Company recorded an interest income receivable of approximately $0.6 million on the Raefan Industries Promissory Note as of June 30, 2023 and an unrealized loss on the note of approximately $0.2 million. American Innovative Robotics, LLC Investment The Company recorded interest income of approximately $44,000 on the Robotics Promissory Note for the six months ended June 30, 2023. Kaya Now Inc. Investment During the fourth quarter of 2022, the Company identified indicators of impairment for the Kaya investment as a result of adverse changes in Kaya’s business operations, including liquidity concerns. As a result, the Company recorded an impairment charge of $0.5 million in the fourth quarter of 2022. The impairment charge represents an impairment loss of the total investment held as a promissory note resulting in a $0 balance for the Kaya Now Promissory Note as of June 30, 2023. The Company received and recorded interest income related to the Kaya Now Promissory Note of approximately $10,000 for the six months ended June 30, 2023.

Fair Value of Financial Assets

Fair Value of Financial Assets and Liabilities	6 Months Ended
	Jun. 30, 2023
Fair Value of Financial Assets and Liabilities [Abstract]
Fair Value of Financial Assets and Liabilities	Note 9. Fair Value of Financial Assets and Liabilities Financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. The Company uses three levels of inputs that may be used to measure fair value: Level 1 - quoted prices in active markets for identical assets or liabilities Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 - inputs that are unobservable (for example, cash flow modeling inputs based on assumptions) Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment. The following table presents the Company’s assets and liabilities that are measured at fair value as of June 30, 2023, and December 31, 2022 ($ in thousands): Fair value measured as of June 30, 2023 Total at Quoted Significant other Significant unobservable inputs 2023 (Level 1) (Level 2) (Level 3) Assets Marketable securities: Equities $ 20,675 $ 20,675 $ - $ - Total marketable securities $ 20,675 $ 20,675 $ - $ - Short-term investment $ 13 $ - $ - $ 13 Notes receivable at fair value, current portion $ 6,339 $ - $ - $ 6,339 Notes receivable at fair value, non-current portion $ 1,622 $ - $ - $ 1,622 Fair value measured as of December 31, 2022 Total at Quoted Significant other Significant 2022 (Level 1) (Level 2) (Level 3) Assets Marketable securities: Equities $ 7,130 $ 7,130 $ - $ - Total marketable securities $ 7,130 $ 7,130 $ - $ - Short-term investment $ 13 $ - $ - $ 13 Notes receivable at fair value, current portion $ 7,474 $ - $ - $ 7,474 Notes receivable at fair value, non-current portion $ 1,100 $ - $ - $ 1,100 Level 3 Measurement The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis ($ in thousands): Short-term investment at December 31, 2022 $ 13 Short-term investment at June 30, 2023 $ 13 Notes receivable at fair value, current portion at December 31, 2022 $ 7,474 Collection of principal outstanding (500 ) Note receivable, Convergent Therapeutics, non-current portion (500 ) Unrealized loss on note receivable (212 ) Accrued interest receivable 77 Notes receivable at fair value, current portion at June 30, 2023 $ 6,339 Notes receivable at fair value, non-current portion at December 31, 2022 $ 1,100 Note receivable, Convergent Therapeutics, non-current portion 500 Accrued interest receivable 22 Notes receivable at fair value, non-current portion at June 30, 2023 $ 1,622 Note Receivable at fair value As of June 30, 2023, the fair value of the notes receivable was measured taking into consideration cost of the investment, market participant inputs, market conditions, liquidity, operating results and other qualitative and quantitative factors. No material change was noted in the fair value of the notes receivable during the three months ended June 30, 2023.

Leases

Leases	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Leases	Note 10. Leases On December 1, 2021, the Company entered into a Lease Agreement (the “Company’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under the Company’s Lease, the Company rents a portion of the twenty-second floor at 725 Fifth Avenue, New York, New York (the “22 nd nd nd On September 23, 2022, Dominari Financial entered into a Lease Agreement (“Dominari Financial’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under Dominari Financial’s Lease, Dominari Financial rents a portion of a floor at 725 Fifth Avenue, New York, New York (the “Premises”). Dominari Financial currently uses the Premises to run its day-to-day operations. The initial term of Dominari Financial’s Lease is seven (7) years commencing on the date that possession of the Premises is delivered to Dominari Financial. Under Dominari Financial’s Lease, Dominari Financial is required to pay monthly rent equal to $49,368. Effective for the sixth and seventh years of Dominari Financial’s Lease, the rent shall increase to $51,868 per month. The Company took possession of the Premises in February 2023. The tables below represent the Company’s lease assets and liabilities as of June 30, 2023: June 30, Assets: Operating lease right-of-use-assets $ 3,530 Liabilities: Current Operating 353 Long-term Operating 3,259 $ 3,612 The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC 842: June 30, 2023 Weighted-average remaining lease term – operating leases (in years) 7.0 Weighted-average discount rate – operating leases 10.0 % During the six months ended June 30, 2023, the Company recorded approximately $0.4 million of lease expense to current period operations. Three Months Ended Six Months Ended June 30, June 30, Operating leases Operating lease cost $ 179 $ 313 Operating lease expense 179 313 Short-term lease rent expense 33 63 Net rent expense $ 212 $ 376 Supplemental cash flow information related to leases were as follows: Six Months June 30, Operating cash flows - operating leases $ 72 Right-of-use assets obtained in exchange for operating lease liabilities $ 2,796 As of June 30, 2023, future minimum payments during the next five years and thereafter are as follows: Operating Leases Remaining Period Ended December 31, 2023 $ 327 Year Ended December 31, 2024 750 Year Ended December 31, 2025 688 Year Ended December 31, 2026 688 Year Ended December 31, 2027 688 Year Ended December 31, 2028 770 Thereafter 1,166 Total 5,077 Less present value discount (1,465 ) Operating lease liabilities $ 3,612

Net Loss per Share

Net Loss per Share	6 Months Ended
	Jun. 30, 2023
Net Loss per Share [Abstract]
Net Loss per Share	Note 11. Net Loss per Share Basic loss per share of common stock is computed by dividing the net loss allocable to common stockholders by the weighted-average number of shares of common stock or common stock equivalents outstanding. Diluted loss per common share is computed similar to basic loss per share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the six months ended June 30, 2023, and 2022 are as follows: As of June 30, 2023 2022 Convertible preferred stock 34 34 Warrants to purchase common stock 444,796 444,796 Options to purchase common stock 30,336 198,574 Total 475,166 643,404

Stockholders_ Equity and Conver

Stockholders’ Equity and Convertible Preferred Stock	6 Months Ended
	Jun. 30, 2023
Stockholders’ Equity and Convertible Preferred Stock [Abstract]
Stockholders’ Equity and Convertible Preferred Stock	Note 12. Stockholders’ Equity and Convertible Preferred Stock Common Stock On March 6, 2023, the Company cancelled 644,499 shares of common stock as a result of retirement of 644,499 shares of treasury stock. On March 20, 2023, the Company cancelled 25,000 shares of common stock owned by a board member. June 27, 2023, pursuant to Soo Yu’s employment agreement and the Company’s 2022 Equity Incentive Plan, the Company executed a Grant Agreement, through which Soo Yu was granted 1,033,591 shares of the Company’s common stock. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value of approximately $2.7 million. Pursuant to the Grant Agreement, the Company withheld 503,876 of the shares granted to satisfy Soo Yu’s tax obligation of approximately $1.3 million and recorded as income taxes withheld within the unaudited condensed consolidated balance sheet. See Restricted Stock roll-forward below. Treasury Stock On January 21, 2022, the Company’s board of directors authorized a share buyback program (the “Share Buyback Program”), pursuant to which the Company authorized the Share Buyback Program in an amount of up to three million dollars. During the six months ended June 30, 2023, the Company repurchased 236,630 shares at a cost of approximately $0.9 million or $3.97 per share through marketable securities account under the Share Buyback Program. The Company records treasury stock using the cost method. On March 6, 2023, the Company retired 644,499 shares of treasury stock with original cost of approximately $3.8 million. Warrants A summary of warrant activity for the six months ended June 30, 2023, is presented below: Warrants Weighted Total Weighted Outstanding as of December 31, 2022 444,796 $ 29.25 - 3.20 Outstanding as of June 30, 2023 444,796 $ 29.25 - 2.71 Restricted Stock Awards A summary of restricted stock awards activity for the six months ended June 30, 2023, is presented below: Number of Restricted Weighted Average Nonvested at December 31, 2022 8,068 $ 5.64 Granted 529,715 $ 2.58 Vested (537,783 ) 2.63 Nonvested at June 30, 2023 - $ - As of June 30, 2023, there is no unrecognized stock-based compensation expense related to restricted stock awards. Stock Options A summary of option activity under the Company’s stock option plan for the six months ended June 30, 2023 is presented below: Number of Shares Weighted Average Total Intrinsic Value Weighted Average Outstanding as of December 31, 2022 31,193 $ 302.97 $ - 7.9 Employee options expired (857 ) $ 9,719.07 Outstanding as of June 30, 2023 30,336 $ 36.97 $ - 7.6 Options vested and exercisable 26,578 $ 41.35 $ - 7.5 Stock-based compensation associated with the amortization of stock option expense was approximately $8,000 and $0 for the six months ended June 30, 2023, and 2022, respectively. All stock compensation was recorded as a component of general and administrative expenses. Estimated future stock-based compensation expense relating to unvested stock options is approximately $7,000.

Revenue

Revenue	6 Months Ended
	Jun. 30, 2023
Revenue [Abstract]
Revenue	Note 13. Revenue The following table presents our total revenues disaggregated by revenue type for the three and six months ended June 30, 2023 and 2022 (in thousands): Three Months Ended Six Months Ended 2023 2022 2023 2022 Underwriting $ 43 $ - $ 43 $ - Commissions 14 - 14 - Other 14 - $ 14 - Total $ 71 $ - $ 71 $ -

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies [Abstract]
Commitments and Contingencies	Note 14. Commitments and Contingencies Legal Proceedings In the past, in the ordinary course of business, the Company actively pursued legal remedies to enforce its intellectual property rights and to stop unauthorized use of the Company’s technology. Other than ordinary routine litigation incidental to the business, the Company is not aware of any material, active or pending legal proceedings brought against it.

Regulatory

Regulatory	6 Months Ended
	Jun. 30, 2023
Regulatory [Abstract]
Regulatory	Note 15. Regulatory Dominari Securities, the Company’s broker-dealer subsidiary, is registered with the SEC as an introducing broker-dealer and is a member of FINRA. The Company’s broker-dealer subsidiary is subject to SEC Uniform Net Capital Rule (Rule 15c3-1) which requires the maintenance of minimum net capital and requires that the ratio of aggregate indebtedness to net capital, both as defined, shall not exceed 15 to 1. As such, the subsidiary is subject to the minimum net capital requirements promulgated by the SEC and has elected to calculate minimum capital requirements using the basic method permitted by Rule 15c3-1. As of June 30, 2023, Dominari Securities had net capital of approximately $7.3 million, which was approximately $7.2 million in excess of required minimum net capital of $0.1 million.

Related Party Transaction

Related Party Transaction	6 Months Ended
	Jun. 30, 2023
Related Party Transaction [Abstract]
Related Party Transaction	Note 16. Related Party Transaction In 2021, the Company engaged the services of Revere Securities, LLC (“Revere”) to strategically manage and build the Company’s investment processes. Kyle Wool, Board Member, is also a member of the board of directors of Revere. The Company incurred fees of approximately $0.08 million and $0.6 million during the six months ending June 30, 2023, and 2022, respectively. These fees were included in general and administrative expense in the unaudited condensed consolidated statements of operations.

Segment Reporting

Segment Reporting	6 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Segment Reporting	Note 17. Segment Reporting The Company operates in two reportable business segments: (1) Dominari Securities and (2) Legacy AIkido Pharma. The Dominari Securities reportable business segment represents the Company’s broker-dealer business, which is composed of underwriting and transactional service activities. The Legacy AIkido Pharma reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. Prior to the FPS Acquisition, the Company operated as a single operating segment comprised of Legacy AIkido Pharma. The chief operating decision-maker (“CODM”) has access to and regularly reviews internal financial reporting for each business and uses that information to make operational decisions and allocate resources. Accounting policies applied by the reportable segments are the same as those used by the Company and described in the “ Summary of Significant Accounting Policies. The measures of segment profitability that are most relied upon by the CODM are gross revenues and net loss, as presented within the table below and reconciled to the statement of operations. Three Months Ended June 30, 2023 Dominari Securities Legacy AIkido Pharma Consolidated Revenue $ 71 $ - $ 71 Operating Costs General and administrative 6,957 2,123 $ 9,080 Research and development 2 2 Loss from operations $ (6,886 ) $ (2,125 ) $ (9,011 ) Other (expenses) income Other income - Interest income 44 116 160 Loss on marketable securities 400 400 Unrealized loss on note receivable (212 ) (212 ) Total other (expenses) income $ 44 $ 304 $ 348 Net loss $ (6,842 ) $ (1,821 ) $ (8,663 ) Six Months Ended June 30, 2023 Dominari Securities Legacy AIkido Pharma Consolidated Revenue $ 71 $ - $ 71 Operating Costs General and administrative 8,056 4,857 12,913 Research and development 3 3 Loss from operations $ (7,985 ) $ (4,860 ) $ (12,845 ) Other (expenses) income Other income - - Interest income 44 253 297 Loss on marketable securities 335 335 Unrealized loss on note receivable (212 ) (212 ) Total other (expenses) income $ 44 $ 376 $ 420 Net loss $ (7,941 ) $ (4,484 ) $ (12,425 )

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”), and in conformity with the rules and regulations of the SEC. In the opinion of management, these financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the results of the interim periods presented. The condensed balance sheet at December 31, 2022, was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements. Accordingly, these financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aikido Labs, Dominari Financial, and Dominari Securities. All significant intercompany balances and transactions have been eliminated in consolidation. Results for interim periods are not necessarily indicative of results to be expected for a full year or any future period.
Use of Estimates	Use of Estimates The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, the valuation of investments, the valuation of notes receivable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.
Deposits with clearing broker	Deposits with clearing broker Deposits with Dominari Securities’ clearing broker consisted of approximately $7.1 million held in money market funds and liquid insured deposits maintained by the Company with its clearing broker as of June 30, 2023.
Leases	Leases The Company accounts for its leases under ASC 842, Leases Leases
Revenue	Revenue The Company recognizes revenues under ASC 606 - Revenue from Contracts with Customers . The following provides detailed information on the recognition of the Company’s revenues from contracts with customers: ● Underwriting services include underwriting and placement agent services in both the equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenues are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. Costs associated with underwriting transactions are deferred until the related revenue is recognized or the engagement is otherwise concluded and are recorded on a gross basis within the general and administrative line item in the unaudited condensed consolidated statements of operations as the Company is acting as a principal in the arrangement. Any expenses reimbursed by the Company’s clients are recognized as other income. ● Commissions are earned by executing, transactions for clients primarily in equity, equity-related, and debt products. Commission revenues associated with trade execution are recognized at a point in time on trade-date. Commissions revenues are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date.
Recently adopted accounting standards	Recently adopted accounting standards In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers
Effect of new accounting pronouncements not yet adopted	Effect of new accounting pronouncements not yet adopted In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions . In March 2023, the FASB issued ASU 2023-01, Leases
Effect of new accounting pronouncements to be adopted in future periods	Effect of new accounting pronouncements to be adopted in future periods The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these unaudited condensed consolidated financial statements.

FPS Acquisition (Tables)

FPS Acquisition (Tables)	6 Months Ended
	Jun. 30, 2023
FPS Acquisition [Abstract]
Schedule of Fair Values of the Assets Acquired And Liabilities	The following table summarizes the fair values of the assets acquired and liabilities assumed of FPS at the date of acquisition: March 27, 2023 (Unaudited) ASSETS Cash and cash equivalents $ 92 Deposits with Clearing Broker-Dealer 3,550 Other receivables 53 Prepaid and other current assets 89 Total assets acquired 3,784 Liabilities Accrued expenses $ 273 Accrued commissions 25 Wealth management liabilities 62 Total liabilities assumed 360 Total net assets of FPS Acquisition 3,424

Investments in Marketable Sec_2

Investments in Marketable Securities (Tables)	6 Months Ended
	Jun. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Schedule of Marketable Securities	The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the three and six months ended June 30, 2023 and 2022, which are recorded as a component of gains and (losses) on marketable securities on the unaudited condensed consolidated statements of operations, are as follows ($ in thousands): Three Months Ended Six Months Ended 2023 2022 2023 2022 Realized loss $ (432 ) $ (344 ) $ (487 ) $ (568 ) Unrealized gain (loss) 643 (1,967 ) 514 (2,299 ) Dividend income 188 72 308 131 Total $ 400 $ (2,239 ) $ 335 $ (2,736 )

Short-Term Investments (Tables)

Short-Term Investments (Tables)	6 Months Ended
	Jun. 30, 2023
Short-Term Investments [Abstract]
Schedule of Short-Term Investments	The following table presents the Company’s short-term investments as of June 30, 2023, and December 31, 2022 ($ in thousands): June 30, December 31, Investment in Vicinity Motor Corp. 13 13 Total 13 13
Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements Inputs	The following table provides quantitative information regarding Level 3 fair value measurement inputs at their measurement dates: June 30, December 31, Option term (in years) 1.3 1.8 Volatility 76.9 % 76.90 % Risk-free interest rate 4.47 % 4.47 % Expected dividends 0.00 % 0.00 % Stock price $ 0.96 $ 0.96

Long-Term Investments (Tables)

Long-Term Investments (Tables)	6 Months Ended
	Jun. 30, 2023
Long-Term Investments [Abstract]
Schedule of Long-Term Investments	The following table presents the Company’s long-term investments as of June 30, 2023, and December 31, 2022 ($ in thousands): Cost Basis June 30, December 31, Investment in Kerna Health Inc $ 2,140 $ 4,940 $ 4,940 Investment in Kaya Now 1,500 - - Investment in Tevva Motors 1,972 2,794 2,794 Investment in ASP Isotopes 1,300 - - Investment in AerocarveUS Corporation 1,075 1,075 1,000 Investment in Qxpress 1,000 1,000 1,000 Investment in Masterclass 170 170 170 Investment in Kraken 597 597 597 Investment in Epic Games 3,500 3,500 3,500 Investment in Tesspay 1,240 2,500 2,500 Investment in SpaceX 3,500 3,674 3,674 Investment in Databricks 1,200 1,200 1,200 Investment in Discord 476 476 476 Investment in Thrasio 300 300 300 Investment in Automation Anywhere 476 476 476 Investment in Anduril 476 476 476 Total $ 20,922 $ 23,178 $ 23,103

Notes Receivable (Tables)

Notes Receivable (Tables)	6 Months Ended
	Jun. 30, 2023
Notes Receivable [Abstract]
Schedule of Notes Receivable	The following table presents the Company’s notes receivable as of June 30, 2023 ($ in thousands): Maturity Date Stated Interest Rate Principal Amount Interest Receivable Fair Value Notes receivable, at fair value Convergent convertible note - current 01/29/2023 8 % $ 1,000 $ 199 $ 1,199 Convergent convertible note - non-current 01/29/2023 8 % $ 500 $ - $ 500 Raefan Industries LLC Investment 12/31/2023 8 % $ 4,518 $ 623 $ 5,141 American Innovative Robotics Investment 04/01/2027 8 % $ 1,100 $ 22 $ 1,122 Notes receivable, at fair value - current portion $ 6,339 Notes receivable, at fair value - non-current portion $ 1,622

Fair Value of Financial Asset_2

Fair Value of Financial Assets and Liabilities (Tables)	6 Months Ended
	Jun. 30, 2023
Fair Value of Financial Assets and Liabilities [Abstract]
Schedule of Fair Value Assets and Liabilities	The following table presents the Company’s assets and liabilities that are measured at fair value as of June 30, 2023, and December 31, 2022 ($ in thousands): Fair value measured as of June 30, 2023 Total at Quoted Significant other Significant unobservable inputs 2023 (Level 1) (Level 2) (Level 3) Assets Marketable securities: Equities $ 20,675 $ 20,675 $ - $ - Total marketable securities $ 20,675 $ 20,675 $ - $ - Short-term investment $ 13 $ - $ - $ 13 Notes receivable at fair value, current portion $ 6,339 $ - $ - $ 6,339 Notes receivable at fair value, non-current portion $ 1,622 $ - $ - $ 1,622 Fair value measured as of December 31, 2022 Total at Quoted Significant other Significant 2022 (Level 1) (Level 2) (Level 3) Assets Marketable securities: Equities $ 7,130 $ 7,130 $ - $ - Total marketable securities $ 7,130 $ 7,130 $ - $ - Short-term investment $ 13 $ - $ - $ 13 Notes receivable at fair value, current portion $ 7,474 $ - $ - $ 7,474 Notes receivable at fair value, non-current portion $ 1,100 $ - $ - $ 1,100
Schedule of Fair Value on a Recurring Basis	The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis ($ in thousands): Short-term investment at December 31, 2022 $ 13 Short-term investment at June 30, 2023 $ 13 Notes receivable at fair value, current portion at December 31, 2022 $ 7,474 Collection of principal outstanding (500 ) Note receivable, Convergent Therapeutics, non-current portion (500 ) Unrealized loss on note receivable (212 ) Accrued interest receivable 77 Notes receivable at fair value, current portion at June 30, 2023 $ 6,339 Notes receivable at fair value, non-current portion at December 31, 2022 $ 1,100 Note receivable, Convergent Therapeutics, non-current portion 500 Accrued interest receivable 22 Notes receivable at fair value, non-current portion at June 30, 2023 $ 1,622

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Schedule of Lease Assets and Liabilities	The tables below represent the Company’s lease assets and liabilities as of June 30, 2023: June 30, Assets: Operating lease right-of-use-assets $ 3,530 Liabilities: Current Operating 353 Long-term Operating 3,259 $ 3,612
Schedule of Summarize Quantitative Information about The Company’s Operating Leases	The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC 842: June 30, 2023 Weighted-average remaining lease term – operating leases (in years) 7.0 Weighted-average discount rate – operating leases 10.0 %
Schedule of Lease Expense to Current Period Operations	During the six months ended June 30, 2023, the Company recorded approximately $0.4 million of lease expense to current period operations. Three Months Ended Six Months Ended June 30, June 30, Operating leases Operating lease cost $ 179 $ 313 Operating lease expense 179 313 Short-term lease rent expense 33 63 Net rent expense $ 212 $ 376
Schedule of Supplemental Cash Flow Information Related To Leases	Supplemental cash flow information related to leases were as follows: Six Months June 30, Operating cash flows - operating leases $ 72 Right-of-use assets obtained in exchange for operating lease liabilities $ 2,796
Schedule of Future Minimum Payments	As of June 30, 2023, future minimum payments during the next five years and thereafter are as follows: Operating Leases Remaining Period Ended December 31, 2023 $ 327 Year Ended December 31, 2024 750 Year Ended December 31, 2025 688 Year Ended December 31, 2026 688 Year Ended December 31, 2027 688 Year Ended December 31, 2028 770 Thereafter 1,166 Total 5,077 Less present value discount (1,465 ) Operating lease liabilities $ 3,612

Net Loss per Share (Tables)

Net Loss per Share (Tables)	6 Months Ended
	Jun. 30, 2023
Net Loss per Share [Abstract]
Schedule of Computation of Diluted Loss Per Share	Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the six months ended June 30, 2023, and 2022 are as follows: As of June 30, 2023 2022 Convertible preferred stock 34 34 Warrants to purchase common stock 444,796 444,796 Options to purchase common stock 30,336 198,574 Total 475,166 643,404

Stockholders_ Equity and Conv_2

Stockholders’ Equity and Convertible Preferred Stock (Tables)	6 Months Ended
	Jun. 30, 2023
Stockholders’ Equity and Convertible Preferred Stock [Abstract]
Schedule of Warrant Activity	A summary of warrant activity for the six months ended June 30, 2023, is presented below: Warrants Weighted Total Weighted Outstanding as of December 31, 2022 444,796 $ 29.25 - 3.20 Outstanding as of June 30, 2023 444,796 $ 29.25 - 2.71
Schedule of Restricted Stock Awards Activity	A summary of restricted stock awards activity for the six months ended June 30, 2023, is presented below: Number of Restricted Weighted Average Nonvested at December 31, 2022 8,068 $ 5.64 Granted 529,715 $ 2.58 Vested (537,783 ) 2.63 Nonvested at June 30, 2023 - $ -
Schedule of Stock Option Activity	A summary of option activity under the Company’s stock option plan for the six months ended June 30, 2023 is presented below: Number of Shares Weighted Average Total Intrinsic Value Weighted Average Outstanding as of December 31, 2022 31,193 $ 302.97 $ - 7.9 Employee options expired (857 ) $ 9,719.07 Outstanding as of June 30, 2023 30,336 $ 36.97 $ - 7.6 Options vested and exercisable 26,578 $ 41.35 $ - 7.5

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Jun. 30, 2023
Revenue [Abstract]
Schedule of Total Revenues Disaggregated By Revenue	The following table presents our total revenues disaggregated by revenue type for the three and six months ended June 30, 2023 and 2022 (in thousands): Three Months Ended Six Months Ended 2023 2022 2023 2022 Underwriting $ 43 $ - $ 43 $ - Commissions 14 - 14 - Other 14 - $ 14 - Total $ 71 $ - $ 71 $ -

Segment Reporting (Tables)

Segment Reporting (Tables)	6 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Schedule of Segment Profitability That Are Most Relied Upon By the Codm Are Gross Revenues and Net Loss	The measures of segment profitability that are most relied upon by the CODM are gross revenues and net loss, as presented within the table below and reconciled to the statement of operations. Three Months Ended June 30, 2023 Dominari Securities Legacy AIkido Pharma Consolidated Revenue $ 71 $ - $ 71 Operating Costs General and administrative 6,957 2,123 $ 9,080 Research and development 2 2 Loss from operations $ (6,886 ) $ (2,125 ) $ (9,011 ) Other (expenses) income Other income - Interest income 44 116 160 Loss on marketable securities 400 400 Unrealized loss on note receivable (212 ) (212 ) Total other (expenses) income $ 44 $ 304 $ 348 Net loss $ (6,842 ) $ (1,821 ) $ (8,663 ) Six Months Ended June 30, 2023 Dominari Securities Legacy AIkido Pharma Consolidated Revenue $ 71 $ - $ 71 Operating Costs General and administrative 8,056 4,857 12,913 Research and development 3 3 Loss from operations $ (7,985 ) $ (4,860 ) $ (12,845 ) Other (expenses) income Other income - - Interest income 44 253 297 Loss on marketable securities 335 335 Unrealized loss on note receivable (212 ) (212 ) Total other (expenses) income $ 44 $ 376 $ 420 Net loss $ (7,941 ) $ (4,484 ) $ (12,425 )

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Details) $ in Millions	Jun. 30, 2023 USD ($)
Accounting Policies [Abstract]
Money market funds	$ 7.1

FPS Acquisition (Details)

FPS Acquisition (Details) - USD ($)		6 Months Ended
	Oct. 04, 2022	Jun. 30, 2023	Sep. 09, 2022
FPS Acquisition (Details) [Line Items]
Cash		$ 3,400,000
Transaction costs		900,000
Net loss		7,700,000
Revenue		70,000
Professional service costs		$ 5,400,000
FPS Purchase Agreement [Member]
FPS Acquisition (Details) [Line Items]
Membership interests rate	20%	80%	100%
Consideration amount	$ 2,000,000
Additional consideration		$ 1,600,000
Percentage of acquired membership interest		100%
Cash		$ 3,600,000
Purchase price		1
Net assets		3,400,000
Receivable amount		200,000
Transaction costs		$ 300,000

FPS Acquisition (Details) - Sch

FPS Acquisition (Details) - Schedule of Fair Values of the Assets Acquired And Liabilities - Business Combination [Member] $ in Thousands	Mar. 27, 2023 USD ($)
ASSETS
Cash and cash equivalents	$ 92
Deposits with Clearing Broker-Dealer	3,550
Other receivables	53
Prepaid and other current assets	89
Total assets acquired	3,784
Liabilities
Accrued expenses	273
Accrued commissions	25
Wealth management liabilities	62
Total liabilities assumed	360
Total net assets of FPS Acquisition	$ 3,424

Investments in Marketable Sec_3

Investments in Marketable Securities (Details) - Schedule of Marketable Securities - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Schedule of marketable securities [Abstract]
Realized loss	$ (432)	$ (344)	$ (487)	$ (568)
Unrealized gain (loss)	643	(1,967)	514	(2,299)
Dividend income	188	72	308	131
Total	$ 400	$ (2,239)	$ 335	$ (2,736)

Short-Term Investments (Details

Short-Term Investments (Details) - Schedule of Short-Term Investments - Investment in Vicinity Motor Corp. [Member] - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Short-Term Investments (Details) - Schedule of Short-Term Investments [Line Items]
Investment in Vicinity Motor Corp.	$ 13	$ 13
Total	$ 13	$ 13

Short-Term Investments (Detai_2

Short-Term Investments (Details) - Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements Inputs - Vicinity Motor Corp [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Short-Term Investments (Details) - Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements Inputs [Line Items]
Option term (in years)	1 year 3 months 18 days	1 year 9 months 18 days
Volatility	76.90%	76.90%
Risk-free interest rate	4.47%	4.47%
Expected dividends	0%	0%
Stock price (in Dollars per share)	$ 0.96	$ 0.96

Long-Term Investments (Details)

Long-Term Investments (Details) - USD ($) $ in Thousands		1 Months Ended
	Nov. 22, 2021	Jun. 30, 2023	Mar. 31, 2023
Long-Term Investments [Abstract]
Purchase shares	250,000		64,377
Purchase amount	$ 1,000	$ 80
Additional purchased shares		150,000
Investment		$ 1,080

Long-Term Investments (Detail_2

Long-Term Investments (Details) - Schedule of Long-Term Investments - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	$ 20,922
Long-term investments, Total	23,178	$ 23,103
Investment In Kerna Health Inc [Member]
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	2,140
Long-term investments, Total	4,940	4,940
Investment in Kaya Now [Member]
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	1,500
Long-term investments, Total
Investment in Tevva Motors [Member]
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	1,972
Long-term investments, Total	2,794	2,794
Investment in ASP Isotopes [Member]
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	1,300
Long-term investments, Total
Investment in AerocarveUS Corporation [Member]
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	1,075
Long-term investments, Total	1,075	1,000
Investment in Qxpress [Member]
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	1,000
Long-term investments, Total	1,000	1,000
Investment in Masterclass [Member]
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	170
Long-term investments, Total	170	170
Investment in Kraken [Member]
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	597
Long-term investments, Total	597	597
Investment in Epic Games [Member]
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	3,500
Long-term investments, Total	3,500	3,500
Investment in Tesspay [Member]
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	1,240
Long-term investments, Total	2,500	2,500
Investment in SpaceX [Member]
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	3,500
Long-term investments, Total	3,674	3,674
Investment in Databricks [Member]
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	1,200
Long-term investments, Total	1,200	1,200
Investment in Discord [Member]
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	476
Long-term investments, Total	476	476
Investment in Thrasio [Member]
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	300
Long-term investments, Total	300	300
Investment in Automation Anywhere [Member]
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	476
Long-term investments, Total	476	476
Investment in Anduril [Member]
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	476
Long-term investments, Total	$ 476	$ 476

Notes Receivable (Details)

Notes Receivable (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Notes Receivable (Details) [Line Items]
Principal amount	$ 1,800,000
Accrued interest	250,000
Interest income	100,000
Impairment loss	$ 0
Convergent Therapeutics, Inc. Investment [Member]
Notes Receivable (Details) [Line Items]
Convertible promissory note percentage	8%
Promissory note maturity date	Jan. 29, 2023
Principal amount	$ 1,800,000
Convergent Therapeutics, Inc. Investment [Member] | Notes Payable [Member]
Notes Receivable (Details) [Line Items]
Principal amount	500,000
Raefan Industries LLC Investment [Member]
Notes Receivable (Details) [Line Items]
Interest income receivable	600,000
Unrealized loss	200,000
American Innovative Robotics, LLC Investment [Member]
Notes Receivable (Details) [Line Items]
Interest income	44,000
Impairment charges		$ 500,000
Kaya Now Promissory Note [Member]
Notes Receivable (Details) [Line Items]
Interest income	$ 10,000

Notes Receivable (Details) - Sc

Notes Receivable (Details) - Schedule of Notes Receivable $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Convergent Convertible Note - Current [Member]
Notes receivable, at fair value
Maturity Date	Jan. 29, 2023
Stated Interest Rate	8%
Principal Amount	$ 1,000
Interest Receivable	199
Fair Value	$ 1,199
Convergent Convertible Note - Non-Current [Member]
Notes receivable, at fair value
Maturity Date	Jan. 29, 2023
Stated Interest Rate	8%
Principal Amount	$ 500
Interest Receivable
Fair Value	$ 500
Raefan Industries LLC Investment [Member]
Notes receivable, at fair value
Maturity Date	Dec. 31, 2023
Stated Interest Rate	8%
Principal Amount	$ 4,518
Interest Receivable	623
Fair Value	$ 5,141
American Innovative Robotics Investment [Member]
Notes receivable, at fair value
Maturity Date	Apr. 01, 2027
Stated Interest Rate	8%
Principal Amount	$ 1,100
Interest Receivable	22
Fair Value	1,122
Notes Receivable, at Fair Value - Current Portion [Member]
Notes receivable, at fair value
Fair Value	6,339
Notes Receivable, at Fair Value - Non-Current Portion [Member]
Notes receivable, at fair value
Fair Value	$ 1,622

Fair Value of Financial Asset_3

Fair Value of Financial Assets and Liabilities (Details) - Schedule of Fair Value Assets and Liabilities - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Marketable securities:
Equities	$ 20,675	$ 7,130
Total marketable securities	20,675	7,130
Short-term investment	13	13
Notes receivable at fair value, current portion	6,339	7,474
Notes receivable at fair value, non-current portion	1,622	1,100
Quoted prices in active markets (Level 1) [Member]
Marketable securities:
Equities	20,675	7,130
Total marketable securities	20,675	7,130
Short-term investment
Notes receivable at fair value, current portion
Notes receivable at fair value, non-current portion
Significant other observable inputs (Level 2) [Member]
Marketable securities:
Equities
Total marketable securities
Short-term investment
Notes receivable at fair value, current portion
Notes receivable at fair value, non-current portion
Significant unobservable inputs (Level 3) [Member]
Marketable securities:
Equities
Total marketable securities
Short-term investment	13	13
Notes receivable at fair value, current portion	6,339	7,474
Notes receivable at fair value, non-current portion	$ 1,622	$ 1,100

Fair Value of Financial Asset_4

Fair Value of Financial Assets and Liabilities (Details) - Schedule of Fair Value on a Recurring Basis - Fair Value, Inputs, Level 3 [Member] - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Short-term investment at December 31, 2022	$ 13
Short-term investment at June 30, 2023	13
Notes receivable at fair value, current portion at December 31, 2022	7,474
Notes receivable at fair value, non-current portion at December 31, 2022	1,100
Collection of principal outstanding	(500)
Note receivable, Convergent Therapeutics, non-current portion	(500)
Unrealized loss on note receivable	(212)
Accrued interest receivable	77
Notes receivable at fair value, current portion at June 30, 2023	6,339
Note receivable, Convergent Therapeutics, non-current portion	500
Accrued interest receivable	22
Notes receivable at fair value, non-current portion at June 30, 2023	$ 1,622

Leases (Details)

Leases (Details) - USD ($)		6 Months Ended
	Sep. 23, 2022	Jun. 30, 2023	Jan. 11, 2023
Leases [Abstract]
Lease commencement date, description		The initial term of the Company’s Lease is seven (7) years commencing on July 11, 2022 (“Commencement Date).
Rent payment	$ 49,368		$ 12,874
Increase rent amount	$ 51,868	$ 13,502
Lease cost		$ 400,000
Lease term		5 years

Leases (Details) - Schedule of

Leases (Details) - Schedule of Lease Assets and Liabilities - Operating lease [Member] $ in Thousands	Jun. 30, 2023 USD ($)
Assets:
Operating lease right-of-use-assets	$ 3,530
Liabilities:
Current operating liabilities	353
Long -term operating liabilities	3,259
Total	$ 3,612

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of Summarize Quantitative Information about The Company’s Operating Leases	Jun. 30, 2023
Schedule of summarize quantitative information about the company’s operating leases [Abstract]
Weighted-average remaining lease term – operating leases (in years)	7 years
Weighted-average discount rate – operating leases	10%

Leases (Details) - Schedule o_3

Leases (Details) - Schedule of Lease Expense to Current Period Operations - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023
Operating leases
Operating lease cost	$ 179	$ 313
Operating lease expense	179	313
Short-term lease rent expense	33	63
Net rent expense	$ 212	$ 376

Leases (Details) - Schedule o_4

Leases (Details) - Schedule of Supplemental Cash Flow Information Related To Leases $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Schedule of supplemental cash flow information related to leases [Abstract]
Operating cash flows - operating leases	$ 72
Right-of-use assets obtained in exchange for operating lease liabilities	$ 2,796

Leases (Details) - Schedule o_5

Leases (Details) - Schedule of Future Minimum Payments $ in Thousands	Jun. 30, 2023 USD ($)
Schedule of future minimum payments [Member]
Remaining Period Ended December 31, 2023	$ 327
Year Ended December 31, 2024	750
Year Ended December 31, 2025	688
Year Ended December 31, 2026	688
Year Ended December 31, 2027	688
Year Ended December 31, 2028	770
Thereafter	1,166
Total	5,077
Less present value discount	(1,465)
Operating lease liabilities	$ 3,612

Net Loss per Share (Details) -

Net Loss per Share (Details) - Schedule of Computation of Diluted Loss Per Share - shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	475,166	643,404
Convertible preferred stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	34	34
Warrants to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	444,796	444,796
Options to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	30,336	198,574

Stockholders_ Equity and Conv_3

Stockholders’ Equity and Convertible Preferred Stock (Details) - USD ($)		1 Months Ended		3 Months Ended		6 Months Ended
	Mar. 06, 2023	Jun. 27, 2023	Jan. 21, 2022	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Mar. 20, 2023
Stockholders’ Equity and Convertible Preferred Stock (Details) [Line Items]
Shares cancelled (in Shares)	644,499							25,000
Common stock retirement shares	$ 644,499
Granted shares		$ 503,876
Total fair value		2,700,000
Restricted Stock, Value, Shares Issued Net of Tax Withholdings		1,300,000
Share Buyback Program amount			$ 3,000,000
Share repurchased (in Shares)						236,630
Amount of cost						$ 0.9
Price per share (in Dollars per share)				$ 3.97		$ 3.97
Retired shares of treasury stock (in Shares)	644,499
Original cost	$ 3,800,000
Stock-based compensation expense				$ 1,370,000	$ 105,000	$ 1,375,000	$ 105,000
Estimated future stock-based compensation expense						7,000
Over-Allotment Option [Member]
Stockholders’ Equity and Convertible Preferred Stock (Details) [Line Items]
Stock-based compensation expense						8,000	0
Common Stock [Member]
Stockholders’ Equity and Convertible Preferred Stock (Details) [Line Items]
Granted shares		$ 1,033,591
Stock-based compensation expense

Stockholders_ Equity and Conv_4

Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Warrant Activity - Warrant [Member] - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Class of Warrant or Right [Line Items]
Outstanding beginning balance, Warrants		444,796
Outstanding beginning balance, Weighted Average Exercise Price		$ 29.25
Outstanding beginning balance, Total Intrinsic Value
Outstanding beginning balance, Weighted Average Remaining Contractual Life		3 years 2 months 12 days
Outstanding ending balance, Warrants	444,796
Outstanding ending balance, Weighted Average Exercise Price	$ 29.25
Outstanding ending balance, Total Intrinsic Value
Outstanding ending balance, Weighted Average Remaining Contractual Life	2 years 8 months 15 days

Stockholders_ Equity and Conv_5

Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Restricted Stock Awards Activity	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Restricted Stock Awards Activity [Line Items]
Number of Restricted Stock Awards, beginning balance | shares	8,068
Weighted Average Grant Day Fair Value, beginning balance | $ / shares	$ 5.64
Number of Restricted Stock Awards, ending balance | shares
Weighted Average Grant Day Fair Value, ending balance | $ / shares
Number of Restricted Stock Awards, Granted | shares	529,715
Weighted Average Grant Day Fair Value, Granted | $ / shares	$ 2.58
Number of Restricted Stock Awards, Vested | shares	(537,783)
Weighted Average Grant Day Fair Value, Vested | $ / shares	$ 2.63

Stockholders_ Equity and Conv_6

Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Stock Option Activity	6 Months Ended
	Jun. 30, 2023 USD ($) $ / shares shares
Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Stock Option Activity [Line Items]
Outstanding beginning balance, Number of Shares | shares	31,193
Outstanding beginning balance, Weighted Average Exercise Price | $ / shares	$ 302.97
Outstanding ending balance, Intrinsic Value | $
Outstanding beginning balance, Weighted Average Remaining Contractual Life	7 years 10 months 24 days
Outstanding ending balance, Number of Shares | shares	30,336
Outstanding ending balance, Weighted Average Exercise Price | $ / shares	$ 36.97
Outstanding ending balance, Intrinsic Value | $
Outstanding ending balance, Weighted Average Remaining Contractual Life	7 years 7 months 6 days
Number of Shares, Options vested and exercisable | shares	26,578
Weighted Average Exercise Price, Options vested and exercisable | $ / shares	$ 41.35
Total Intrinsic Value, Options vested and exercisable | $
Weighted Average Remaining Contractual Life (in years), Options vested and exercisable	7 years 6 months
Number of Shares, Employee options expired | shares	(857)
Weighted Average Exercise Price, Employee options expired | $ / shares	$ 9,719.07

Revenue (Details) - Schedule of

Revenue (Details) - Schedule of Total Revenues Disaggregated By Revenue - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Schedule of total revenues disaggregated by revenue [Abstract]
Underwriting	$ 43		$ 43
Commissions	14		14
Other	14		14
Total	$ 71		$ 71

Regulatory (Details)

Regulatory (Details) $ in Millions	Jun. 30, 2023 USD ($)
Regulatory (Details) [Line Items]
Net capital amount	$ 0.1
Excess amount	7.2
Dominari Securities [Member]
Regulatory (Details) [Line Items]
Net capital amount	$ 7.3

Related Party Transaction (Deta

Related Party Transaction (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Related Party Transaction [Abstract]
Incurred fees	$ 80	$ 600

Segment Reporting (Details) - S

Segment Reporting (Details) - Schedule of Segment Profitability That Are Most Relied Upon By the Codm Are Gross Revenues and Net Loss - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023
Dominari Securities [Member]
Segment Reporting Information [Line Items]
Revenue	$ 71	$ 71
Operating Costs
General and administrative	6,957	8,056
Loss from operations	(6,886)	(7,985)
Other (expenses) income
Interest income	44	44
Total other (expenses) income	44	44
Net loss	(6,842)	(7,941)
Legacy AIkido Pharma [Member]
Segment Reporting Information [Line Items]
Revenue
Operating Costs
General and administrative	2,123	4,857
Research and development	2	3
Loss from operations	(2,125)	(4,860)
Other (expenses) income
Other income
Interest income	116	253
Loss on marketable securities	400	335
Unrealized loss on note receivable	(212)	(212)
Total other (expenses) income	304	376
Net loss	(1,821)	(4,484)
Consolidated [Member]
Segment Reporting Information [Line Items]
Revenue	71	71
Operating Costs
General and administrative	9,080	12,913
Research and development	2	3
Loss from operations	(9,011)	(12,845)
Other (expenses) income
Other income
Interest income	160	297
Loss on marketable securities	400	335
Unrealized loss on note receivable	(212)	(212)
Total other (expenses) income	348	420
Net loss	$ (8,663)	$ (12,425)